America’s Essential Hospitals Asks HHS to Swiftly Repay 340B Hospitals for Unlawful Medicare Drug Payment Cuts

America's Essential Hospitals wordmark and tagline
America’s Essential Hospitals wants HHS “to swiftly remedy five years of unlawful drug reimbursement cuts to 340B hospitals under Medicare Part B.”

America’s Essential Hospitals asked U.S. Health and Human Services Secretary Xavier Becerra late last week “to swiftly remedy five years of unlawful drug reimbursement cuts to 340B
hospitals under Medicare Part B.”

“These cuts, and a delay in recompensing hospitals for

Read More »

Iowa Tries Again to End Alleged PBM Bias Against 340B Providers and Pharmacies

Iowa State Capitol building
Iowa lawmakers are debating legislation to bar pharmacy benefit managers and insurers from using alleged discriminatory practices against 340B covered entities and their contract pharmacies.

Identical bills have been introduced in the Iowa House and Senate to bar pharmacy benefit managers and insurers from using alleged discriminatory practices against 340B covered entities and their contract pharmacies, including reimbursing them at a lower rate or imposing

Read More »

J&J Announces Major Expansion of 340B Contract Pharmacy Limits; Pushback Is Likely

Johnson & Johnson signage in front of building
Johnson & Johnson is poised to become the first drug maker to place a condition on 340B sales and deliveries to covered entity in-house pharmacies.

Johnson & Johnson, the world’s biggest drug company, yesterday announced a major expansion of the drug industry’s campaign to set limits on 340B drug sales.

On March 7, it is poised to become the first drug maker to place a

Read More »

Connecticut’s Democratic Governor Wants Hospitals to Report 340B Earnings and Manufacturers to Resume 340B Pricing

A Connecticut state health agency under Gov. Ned Lamont (D) proposed legislation to implement certain 340B provider reporting requirements.

Connecticut’s Democratic governor wants his state’s 340B hospitals to start filing annual reports disclosing their 340B drug revenues and summarizing how they use the money to benefit their communities. Health centers and other 340B grantee covered entities would be exempt

Read More »

Contract Pharmacies: An Integral 340B Component for 30 Years

SPONSORED CONTENT

This past November, the 340B program celebrated its 30th anniversary—a huge milestone and a reason to rejoice and reflect. We are dismayed, however, that certain drug manufacturers are trying to revise the 340B program’s past and reimagine its future. More than 20 drug manufacturers have unilaterally and unlawfully

Read More »

Baldwin, a 340B Entity Ally, Will Chair Senate Health Appropriations Subcommittee

Sen. Tammy Baldwin (D-WI)
U.S. Sen. Tammy Baldwin (D-Wis.) is the new chair of the Senate Labor, Health and Human Services, Education, and Related Agencies Appropriations Subcommittee.

U.S. Sen. Tammy Baldwin (D-Wis.), who has a long track record of support for 340B covered entities, is the new leader of a Senate Appropriations subcommittee with influence over 340B policy.

Baldwin announced yesterday she will serve as chair

Read More »

340B INDUSTRY LEADER SPOTLIGHT

Scott Carruthers, Chief Pharmacy Officer, AIDS Healthcare Foundation

Scott Carruthers headshot
Scott Carruthers

Q: Where did you grow up?

I grew up in Pacific Beach, San Diego, a lovely little beach town.

Q: Where did you go to college?

I attended the University of Southern California.

Q: What are your favorites?

Food: Chili 

Movie: The ShawShank Redemption

Musician: Eric Clapton

Destination: Hawaii

Q: What do you like to do

Read More »

340B Pricing May Be Coming to Contrast Agents, Radiopharmaceuticals, and OTC Monograph Drugs

Contrast media image of kidneys
Providers may get previously unavailable access to 340B pricing on contrast agents, radiopharmaceuticals, and OTC monograph drugs thanks to language in a a federal FY 2023 spending law.

Health care providers in the coming months may get previously unavailable access to 340B pricing on contrast agents, radiopharmaceuticals, and so-called “OTC monograph” drugs thanks to language tucked into the massive fiscal year 2023 federal spending bill signed into law

Read More »

Ex-CMS Leader Verma: Big Health Systems Use 340B to Expand Profit and Monopoly Power

CMS Administrator Seema Verma speaks at White House podium
Health systems use 340B to expand "their profit and monopoly power," Trump administration CMS Administrator Seema Verma said in a Wall Street Journal op-ed.

Seema Verma, ex-President Trump’s Centers for Medicare & Medicaid Services administrator, said in a Wall Street Journal op-ed yesterday that large health systems work to expand their use of the 340B program “and thus their profit and monopoly power.”

“Across

Read More »

CMS Seeks Input on Excluding 340B Drugs from New Medicare Part D Inflation Rebates

Part D inflation rebate press release
CMS is seeking comment on how best to exclude 340B drugs from new Part D inflation rebate invoices.

The U.S. Centers for Medicare & Medicaid Services is seeking comments by March 11 on “the most reliable way to identify” 340B-purchased drugs dispensed to Medicare Part D beneficiaries so they can be excluded from new Part D inflation rebate

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live